Reading Document

Medical Text Search

hypertension management CKD stepwise drug therapy antihypertensive dosing GFR stages

Medical Text Search

CKD drug dosing adjustment eGFR creatinine potassium lab values ACE inhibitor ARB dosage

GradeResponse

Medical Text Search

CKD blood pressure targets proteinuria ACE inhibitor ARB SGLT2 inhibitor finerenone stepwise algorithm

Medical Text Search

renal ultrasound CKD follow up kidney size echogenicity monitoring progression

Now I'll compile a comprehensive, well-structured answer from retrieved sources and my clinical knowledge base.

🫘 Hypertension Management in CKD: Complete Clinical Guide

📊 SECTION 1 — CKD STAGING (Foundation for All Dosing Decisions)

CKD Stage	eGFR (mL/min/1.73m²)	Serum Creatinine (approx.)	Description
G1	≥90	~0.7–1.0	Normal/high — kidney damage present
G2	60–89	~1.0–1.3	Mildly decreased
G3a	45–59	~1.3–1.7	Mildly-moderately decreased
G3b	30–44	~1.7–2.5	Moderately-severely decreased
G4	15–29	~2.5–5.0	Severely decreased
G5	<15	>5.0	Kidney failure / ESRD

Albuminuria Categories (KDIGO):

Category	ACR (mg/g)	Description
A1	<30	Normal to mildly increased
A2	30–300	Moderately increased
A3	>300	Severely increased

🎯 SECTION 2 — BLOOD PRESSURE TARGETS IN CKD

Condition	Target BP
CKD without diabetes, ACR <30 mg/g	<140/90 mmHg
CKD with albuminuria (ACR ≥30)	<130/80 mmHg
CKD with diabetes	<130/80 mmHg
CKD on dialysis	<140/90 mmHg (pre-dialysis)
CKD post-transplant	<130/80 mmHg

2021 KDIGO HTN Guidelines: Standardized BP measurement target of systolic BP <120 mmHg may be appropriate in high-cardiovascular-risk CKD patients if tolerated (SPRINT-CKD data).

💊 SECTION 3 — STEPWISE ANTIHYPERTENSIVE DRUG APPROACH IN CKD

🔷 FLOWCHART: Stepwise Antihypertensive Approach in CKD

┌─────────────────────────────────────────────────────────┐
│            CKD PATIENT WITH HYPERTENSION                │
│         Measure BP (standardized office method)         │
└────────────────────────┬────────────────────────────────┘
                         ▼
        ┌────────────────────────────────┐
        │  Check Baseline Labs:          │
        │  • eGFR / Serum Creatinine     │
        │  • Serum Potassium             │
        │  • Urine ACR (albumin:creat)   │
        │  • Hemoglobin, CBC             │
        │  • Phosphate, Calcium, PTH     │
        │  • Lipids, Blood glucose       │
        └────────────────┬───────────────┘
                         ▼
        ┌────────────────────────────────┐
        │   LIFESTYLE MODIFICATION        │
        │   (All stages — always start)   │
        │  • Sodium <2g/day (<90 mEq/day)│
        │  • DASH or low-protein diet    │
        │  • Weight loss if BMI >25      │
        │  • Aerobic exercise 30 min/day │
        │  • Smoking cessation           │
        │  • Alcohol restriction         │
        └────────────────┬───────────────┘
                         ▼
               BP still above target?
                    ┌──┴──┐
                   YES    NO → Continue monitoring
                    ▼
        ┌───────────────────────────────────┐
        │         STEP 1 DRUG THERAPY        │
        │                                    │
        │  Albuminuria present (ACR ≥30)?   │
        │         ┌────┴────┐               │
        │        YES       NO               │
        │         ▼         ▼               │
        │   ACE inhibitor  CCB or Thiazide  │
        │   OR ARB         (if no           │
        │   (first-line)    contraindication)│
        └────────────────┬──────────────────┘
                         ▼
               BP still above target at 4 wks?
                         ▼
        ┌───────────────────────────────────┐
        │           STEP 2                  │
        │  Add CCB (amlodipine) if on       │
        │  ACEi/ARB, or add ACEi/ARB if     │
        │  on CCB; or add low-dose thiazide │
        │  (chlorthalidone preferred in CKD)│
        └────────────────┬──────────────────┘
                         ▼
               Still not at target?
                         ▼
        ┌───────────────────────────────────┐
        │           STEP 3                  │
        │  Triple therapy:                  │
        │  ACEi/ARB + CCB + Thiazide/loop  │
        │  (Use loop diuretic if eGFR <30) │
        └────────────────┬──────────────────┘
                         ▼
               Still not at target?
                         ▼
        ┌───────────────────────────────────┐
        │           STEP 4                  │
        │  Add Spironolactone 25mg          │
        │  (if K+ <4.5 mEq/L, eGFR >30)   │
        │  OR β-blocker (if heart failure,  │
        │  post-MI, tachycardia)            │
        │  OR α-blocker (BPH + HTN)        │
        │  OR Hydralazine/Minoxidil         │
        └───────────────────────────────────┘

💊 SECTION 4 — DRUG-BY-DRUG DOSING GUIDE IN CKD

🔴 FIRST-LINE: ACE Inhibitors

Drug	Standard Dose	eGFR 30–60	eGFR 15–30	eGFR <15/Dialysis
Ramipril	2.5–10 mg/day	2.5–5 mg/day	1.25–2.5 mg/day	Use with caution; 1.25 mg/day
Enalapril	5–40 mg/day	5–10 mg/day	2.5–5 mg/day	2.5 mg/day (monitor)
Lisinopril	10–40 mg/day	5–10 mg/day	2.5–5 mg/day	2.5 mg/day
Perindopril	4–8 mg/day	2–4 mg/day	2 mg alternate days	Not recommended
Captopril	25–150 mg/day	12.5–75 mg/day	12.5–25 mg/day	6.25–12.5 mg/day

Monitoring: Check K⁺ and creatinine at 1–2 weeks after starting

Allow up to 30% rise in creatinine (acceptable, indicates hemodynamic efficacy)
Stop if: K⁺ >5.5 mEq/L, creatinine rise >30–50%, or bilateral renal artery stenosis suspected

🔴 FIRST-LINE: ARBs (Angiotensin Receptor Blockers)

Drug	Standard Dose	eGFR 30–60	eGFR 15–30	eGFR <15/Dialysis
Losartan	50–100 mg/day	50–100 mg/day	25–50 mg/day	25 mg/day (monitor)
Telmisartan	40–80 mg/day	40–80 mg/day	20–40 mg/day	20 mg/day
Valsartan	80–320 mg/day	80–160 mg/day	40–80 mg/day	40 mg/day
Candesartan	8–32 mg/day	8–16 mg/day	4–8 mg/day	Use cautiously
Olmesartan	20–40 mg/day	20 mg/day	10–20 mg/day	10 mg/day
Irbesartan	150–300 mg/day	150–300 mg/day	75–150 mg/day	75 mg/day

⚠️ Never combine ACEi + ARB (dual RAAS blockade) — increased risk of AKI and hyperkalemia (ONTARGET trial evidence)

🟡 ADD-ON STEP 2: Calcium Channel Blockers

Drug	Standard Dose	CKD G1–G3	CKD G4	CKD G5/Dialysis
Amlodipine	5–10 mg/day	5–10 mg/day	5–10 mg/day	5–10 mg/day (no adjustment)
Nifedipine LA	30–90 mg/day	30–60 mg/day	30–60 mg/day	30–60 mg/day
Felodipine	5–10 mg/day	5–10 mg/day	5 mg/day	5 mg/day
Diltiazem	120–360 mg/day	120–240 mg/day	120 mg/day	Use cautiously
Verapamil	120–360 mg/day	120–240 mg/day	120 mg/day	Reduce dose

DHP-CCBs (amlodipine, nifedipine) preferred over non-DHP (verapamil, diltiazem) when combined with ACEi/ARB in CKD — non-DHPs can increase proteinuria.

🟡 ADD-ON: Diuretics (Critical in CKD — Stage Matters!)

Drug	Standard Dose	eGFR >45	eGFR 30–45	eGFR <30
Chlorthalidone	12.5–25 mg/day	12.5–25 mg	12.5–25 mg	Can try; less effective
Hydrochlorothiazide	12.5–25 mg/day	Effective	Less effective	Avoid (<30)
Indapamide	1.5–2.5 mg/day	Full dose	Full dose	Use cautiously
Furosemide	20–240 mg/day	20–40 mg	40–80 mg	80–160 mg/day (preferred)
Torsemide	5–100 mg/day	10–20 mg	20–40 mg	40–100 mg/day
Bumetanide	0.5–4 mg/day	0.5–1 mg	1–2 mg	2–4 mg/day

⚠️ Key rule: Switch from thiazide to loop diuretic when eGFR falls below 30 — thiazides become ineffective and may worsen electrolyte imbalance at low GFR.

🟠 STEP 3 ADD-ON: Mineralocorticoid Receptor Antagonists

Drug	Type	Dose	eGFR Threshold	K⁺ Monitoring
Spironolactone	Non-selective MRA	12.5–50 mg/day	Use if eGFR >30, K⁺ <4.5	Weekly for 4 weeks, then monthly
Eplerenone	Selective MRA	25–50 mg/day	eGFR >30, K⁺ <4.5	Same as above
Finerenone	Non-steroidal MRA	10–20 mg/day	eGFR ≥25, K⁺ ≤4.8	4 weeks after start

Finerenone: New-generation MRA with FIGARO-DKD and FIDELIO-DKD evidence — reduces cardiovascular events AND CKD progression in diabetic CKD. Start at 10 mg/day if eGFR 25–60; 20 mg/day if eGFR ≥60.

🟠 Beta-Blockers (Selected Indications in CKD)

Drug	Indication in CKD	Dose	CKD Adjustment
Carvedilol	HFrEF + CKD	3.125–25 mg BID	No adjustment needed
Metoprolol succinate	HFrEF, post-MI	25–200 mg/day	No adjustment
Bisoprolol	HF, tachycardia	2.5–10 mg/day	Reduce if eGFR <20
Atenolol	HTN (less preferred)	25–100 mg/day	25 mg if eGFR <30; avoid dialysis
Nebivolol	HTN + HF	2.5–10 mg/day	Caution <30

Atenolol is renally cleared — dose-reduce significantly in CKD G4–G5.

🟤 NEWER AGENTS

Drug	Class	Dose	CKD Role
Empagliflozin	SGLT2i	10 mg/day	eGFR ≥20 for kidney protection; BP lowering ~3–5 mmHg
Dapagliflozin	SGLT2i	10 mg/day	eGFR ≥25 (DAPA-CKD); both diabetic and non-diabetic CKD
Canagliflozin	SGLT2i	100 mg/day	eGFR ≥30 (CREDENCE trial)
Hydralazine	Direct vasodilator	25–75 mg TID	No renal dose adjustment; used in resistant HTN/CKD
Minoxidil	Direct vasodilator	5–40 mg/day	Reserved for resistant HTN; monitor fluid retention
Clonidine	Central α2 agonist	0.1–0.4 mg BID	Use cautiously; reduce in advanced CKD

🔬 SECTION 5 — LAB-GUIDED DRUG DECISION FLOWCHART

┌────────────────────────────────────────────────────────────┐
│               BASELINE / FOLLOW-UP LABS                    │
└────────────────────────────┬───────────────────────────────┘
                             ▼
┌────────────────────────────────────────────────────────────┐
│  1. SERUM POTASSIUM (K⁺)                                   │
│                                                            │
│  K⁺ <4.0 mEq/L                                            │
│    → Safe to start ACEi/ARB/MRA                            │
│    → Can uptitrate to full therapeutic dose                │
│                                                            │
│  K⁺ 4.0–4.5 mEq/L                                         │
│    → Start ACEi/ARB at low dose; add dietary K restriction │
│    → Consider sodium bicarbonate if metabolic acidosis     │
│    → Avoid MRA (spironolactone)                            │
│                                                            │
│  K⁺ 4.6–5.0 mEq/L                                         │
│    → Reduce ACEi/ARB dose                                  │
│    → Patiromer 8.4g/day or SZC (sodium zirconium           │
│      cyclosilicate) 10g TID to enable RAAS therapy         │
│    → Hold MRA                                              │
│                                                            │
│  K⁺ 5.1–5.5 mEq/L                                         │
│    → Hold ACEi/ARB; treat hyperkalemia first               │
│    → Once K⁺ <5.0, restart at lowest dose                 │
│    → Consider patiromer to maintain on RAAS therapy        │
│                                                            │
│  K⁺ >5.5 mEq/L                                            │
│    → Stop ACEi/ARB immediately                             │
│    → Urgent hyperkalemia management                        │
│    → Reassess daily until K⁺ normalizes                   │
└────────────────────────────────────────────────────────────┘

┌────────────────────────────────────────────────────────────┐
│  2. eGFR / CREATININE RESPONSE AFTER ACEi/ARB              │
│                                                            │
│  Creatinine rise <30% from baseline                        │
│    → Acceptable — continue therapy, recheck in 4 weeks    │
│                                                            │
│  Creatinine rise 30–50%                                    │
│    → Investigate: volume depletion? NSAID use?             │
│      bilateral RAS?                                        │
│    → Temporarily hold, optimize volume status,            │
│      re-challenge at lower dose                            │
│                                                            │
│  Creatinine rise >50% or persistent                        │
│    → Discontinue ACEi/ARB                                  │
│    → Renal artery duplex ultrasound to exclude RAS         │
│    → Nephrology referral                                   │
└────────────────────────────────────────────────────────────┘

┌────────────────────────────────────────────────────────────┐
│  3. URINARY ACR (Albumin-Creatinine Ratio)                 │
│                                                            │
│  ACR <30 mg/g (A1)                                         │
│    → No specific renoprotective agent needed               │
│    → CCB or thiazide acceptable first-line                 │
│                                                            │
│  ACR 30–300 mg/g (A2)                                      │
│    → Start ACEi or ARB (first-line mandatory)             │
│    → Add SGLT2i (if eGFR ≥20)                             │
│    → Target BP <130/80                                     │
│                                                            │
│  ACR >300 mg/g (A3)                                        │
│    → Maximize ACEi/ARB dose                               │
│    → Add SGLT2i                                            │
│    → Consider finerenone (especially if DM)               │
│    → Target BP <130/80 (aim <125/75 if tolerated)         │
│    → Loop diuretic if volume overload                      │
└────────────────────────────────────────────────────────────┘

┌────────────────────────────────────────────────────────────┐
│  4. HEMOGLOBIN / ANEMIA                                    │
│                                                            │
│  Hb <10 g/dL                                               │
│    → Start ESA (Erythropoietin/Darbepoetin)               │
│    → Check iron stores (ferritin <200 or TSAT <20%        │
│      → IV iron replacement)                               │
│    → Anemia can worsen hypertension via compensatory       │
│      tachycardia and volume retention                      │
│    → ESA therapy can raise BP — monitor and adjust        │
│      antihypertensives after ESA start                     │
└────────────────────────────────────────────────────────────┘

┌────────────────────────────────────────────────────────────┐
│  5. BICARBONATE / METABOLIC ACIDOSIS                       │
│                                                            │
│  HCO₃⁻ <22 mEq/L                                          │
│    → Start oral sodium bicarbonate 0.5–1 mEq/kg/day      │
│    → Correction of acidosis improves K⁺ handling          │
│      (reduces hyperkalemia risk, enables RAAS therapy)    │
│    → Sodium vaptans/bicarbonate may slightly raise BP —   │
│      monitor BP after starting                            │
└────────────────────────────────────────────────────────────┘

┌────────────────────────────────────────────────────────────┐
│  6. PHOSPHATE / PTH (CKD-MBD Contributing to HTN)         │
│                                                            │
│  Phosphate >4.5 mg/dL (CKD G3–G5)                         │
│    → Dietary phosphate restriction                         │
│    → Phosphate binders:                                    │
│      - Calcium carbonate 500–1500 mg with meals           │
│      - Sevelamer 800–1600 mg TID with meals               │
│      - Lanthanum 500–1000 mg TID                          │
│    → Hyperphosphatemia activates RAAS and contributes     │
│      to vascular calcification and HTN                     │
│                                                            │
│  PTH elevated (secondary hyperparathyroidism)             │
│    → Calcitriol 0.25–0.5 mcg/day (if Ca²⁺ normal)        │
│    → Cinacalcet 30–180 mg/day (in dialysis)               │
└────────────────────────────────────────────────────────────┘

🔊 SECTION 6 — RENAL ULTRASOUND IN CKD FOLLOW-UP

Parameters to Assess on Each Ultrasound

Parameter	Normal	CKD Changes	Clinical Significance
Kidney size	9–12 cm length	Bilaterally small (<9 cm) in advanced CKD	Irreversibility; small kidneys = less reversible disease
Cortical thickness	>7 mm	Thinned cortex in CKD	Correlates with GFR reduction
Echogenicity	Iso-/hypoechoic to liver	Increased echogenicity (bright)	Fibrosis/scarring; correlates with severity
Corticomedullary differentiation	Clear	Lost in advanced CKD	Loss = advanced parenchymal damage
Hydronephrosis	Absent	Present if obstruction	Obstructive uropathy — reverse cause
Cysts	None to few	Multiple in PKD	ADPKD — specific BP targets <110/75 mmHg
Resistive index (RI)	0.58–0.70	>0.70 in CKD	High RI = poor prognosis, correlates with progression
Renal artery flow	Normal PSV	Decreased/absent	Renal artery stenosis if uncontrolled HTN
Bladder/post-void	Empty post-void	Residual urine	Outflow obstruction contributing to CKD

🔷 ULTRASOUND FOLLOW-UP SCHEDULE IN CKD

CKD G1–G2 (eGFR ≥60):
  → Baseline ultrasound at diagnosis
  → Repeat every 2–3 years or if unexplained eGFR decline
  → Focus: Structural abnormalities, hydronephrosis, cysts

CKD G3a–G3b (eGFR 30–59):
  → Ultrasound every 1–2 years
  → Add Doppler to assess RI and renal artery stenosis
  → If BP difficult to control → urgent Doppler for RAS

CKD G4 (eGFR 15–29):
  → Ultrasound every 6–12 months
  → Assess for hydronephrosis, bladder dysfunction
  → Evaluate for AV fistula planning if trending to ESRD
  → Doppler to guide ACEi/ARB safety

CKD G5 / Pre-dialysis (eGFR <15):
  → Ultrasound every 3–6 months
  → Monitor for complications: cysts, stones, abscesses
  → Vascular access planning (fistula maturation assessment)
  → Once on dialysis: annual renal ultrasound

🔷 RENAL ARTERY STENOSIS (RAS) — When to Suspect & Act

Suspect RAS if:

BP refractory to ≥3 agents including a diuretic
Creatinine rise >30% after starting ACEi/ARB
Asymmetric kidneys on ultrasound (>1.5 cm difference)
Flash pulmonary edema episodes
Abdominal bruit on auscultation
Young female with fibromuscular dysplasia features

Investigation:

Renal Doppler ultrasound (first-line, non-invasive)
CT angiography or MR angiography (if Doppler inconclusive)
Gold standard: Digital subtraction angiography (DSA)

🧩 SECTION 7 — COMPLETE INTEGRATED MANAGEMENT FLOWCHART

┌────────────────────────────────────────────────────────────────────┐
│                   CKD + HYPERTENSION — MASTER ALGORITHM           │
└──────────────────────────────┬─────────────────────────────────────┘
                               ▼
              Assess: eGFR, K⁺, ACR, Creatinine, CBC,
              Phosphate, PTH, Bicarbonate, Lipids, HbA1c
                               ▼
                  Renal Ultrasound (Baseline + Doppler)
                               ▼
               ┌───────────────────────────────┐
               │ Lifestyle Modification ALWAYS  │
               │ (Sodium <2g, weight, exercise) │
               └───────────────┬───────────────┘
                               ▼
                    ┌──────────────────┐
                    │  ACR ≥30 mg/g?  │
                    └────┬────────────┘
                        YES            NO
                         ▼              ▼
               ACEi or ARB          CCB (Amlodipine 5mg)
               (Ramipril 2.5–5mg    or Chlorthalidone 12.5mg
                or Losartan 50mg)
                         │              │
                         └──────┬───────┘
                                ▼
                    BP still above target at 4–8 wks?
                                ▼ YES
                  ┌─────────────────────────────────┐
                  │ STEP 2: Combine ACEi/ARB + CCB  │
                  │ (Amlodipine 5–10 mg added)      │
                  └──────────────┬──────────────────┘
                                 ▼
                    BP still above target?
                                 ▼ YES
                  ┌──────────────────────────────────────┐
                  │ STEP 3: Add Diuretic                 │
                  │ eGFR ≥30 → Chlorthalidone 12.5–25mg │
                  │ eGFR <30 → Furosemide 40–80mg BD    │
                  └──────────────┬───────────────────────┘
                                 ▼
              Add SGLT2 inhibitor if eGFR ≥20 (Dapagliflozin 10mg)
                                 ▼
                    BP still uncontrolled?
                                 ▼ YES
                  ┌──────────────────────────────────────┐
                  │ STEP 4: Resistant HTN                │
                  │ Check: adherence, white coat,        │
                  │ secondary causes (RAS, primary       │
                  │ hyperaldosteronism, OSA)             │
                  │                                      │
                  │ Add Spironolactone 12.5–25mg         │
                  │ (if K⁺ <4.5 and eGFR >30)           │
                  │ OR Finerenone 10–20mg                │
                  │ OR β-blocker (Carvedilol 6.25mg BD) │
                  │ OR Minoxidil 5mg (severe cases)      │
                  └──────────────────────────────────────┘
                                 ▼
              MONITOR: Recheck K⁺, creatinine at 2–4 weeks
              ULTRASOUND: Per staging schedule above
              NEPHROLOGY REFERRAL if eGFR <30 or rapid decline

📅 SECTION 8 — MONITORING SCHEDULE SUMMARY

Parameter	Frequency	Action Threshold
BP	Every visit	Adjust meds if outside target
eGFR/Creatinine	Every 3–6 months (G3); monthly (G4–G5)	Stop ACEi/ARB if rise >50%
Serum K⁺	2–4 wks after drug change, then every 3–6 months	>5.5 → stop RAAS; 5.1–5.5 → dose-reduce
Urine ACR	Every 6–12 months	Rising ACR → optimize RAAS + SGLT2i
Hemoglobin	Every 3–6 months	<10 g/dL → ESA + iron
Bicarbonate	Every 3–6 months	<22 → sodium bicarbonate
Phosphate	Every 3–6 months (G3b+)	>4.5 → binders
PTH	Every 6 months (G4–G5)	Elevated → calcitriol/cinacalcet
Renal Ultrasound	Per stage (see above)	New hydronephrosis, RI >0.70 → investigate
Lipids	Annually	Statin in CKD G1–G4 regardless of LDL

⚠️ SECTION 9 — KEY DRUG INTERACTIONS & PRECAUTIONS IN CKD

Combination	Risk	Management
ACEi + ARB	AKI, hyperkalemia	Absolutely contraindicated
ACEi/ARB + NSAIDs	AKI, loss of BP control	Avoid all NSAIDs in CKD
ACEi/ARB + K-sparing diuretic	Severe hyperkalemia	Use with extreme caution; monitor K⁺ weekly
SGLT2i + loop diuretic	Volume depletion	Start SGLT2i at lower volume states carefully
Metformin + CKD	Lactic acidosis	Stop if eGFR <30; reduce dose at eGFR 30–45
Allopurinol in CKD	Toxicity	Reduce to 100 mg/day if eGFR <30
Digoxin in CKD	Toxicity	Use 0.0625–0.125 mg; monitor levels
Spironolactone + ACEi	Hyperkalemia	Use only if K⁺ <4.5 and eGFR >30; weekly K⁺

🏥 SECTION 10 — NEPHROLOGY REFERRAL CRITERIA

Refer to nephrology if:

eGFR <30 mL/min/1.73m² (CKD G4–G5)
Rapid eGFR decline (>5 mL/min/year or >25% in <1 year)
ACR >300 mg/g persistent despite treatment
Uncontrolled HTN despite ≥3 agents
Suspected secondary cause (RAS, GN, ADPKD)
Unexplained AKI on CKD
Preparing for renal replacement therapy (RRT) planning

Sources: Harrison's Principles of Internal Medicine (21st Ed., p. 8499); KDIGO 2021 Blood Pressure in CKD Guidelines; ADA/ADCES Standards of Diabetes Care 2022 (p. 29); FIDELIO-DKD & FIGARO-DKD Trials; DAPA-CKD Trial; CREDENCE Trial; SPRINT-CKD Sub-study; JNC 8 Hypertension Guidelines.

Drugs used in ckd patients for management dosage according to different lab values and ultrasound follow up management of hypertension in ckd patients stepwise approach with drug dosage With flowcharts and drugs used to slow progress of Ckd and other adjunct drugs used. Indication for dialysis frequency and parameters

Medical Text Search

CKD progression slowing drugs SGLT2 inhibitors finerenone ACE inhibitor renoprotection evidence

Medical Text Search

dialysis indications ESRD uremia criteria frequency parameters hemodialysis peritoneal dialysis

GradeResponse

Now I have rich evidence from guidelines and Harrison's. Let me compile the full, expanded guide.

🫘 COMPREHENSIVE CKD MANAGEMENT GUIDE

Hypertension • Drug Dosing • CKD Progression • Adjunct Therapy • Dialysis

📊 SECTION 1 — CKD STAGING (The Foundation)

Stage	eGFR (mL/min/1.73m²)	Creatinine (approx.)	Description
G1	≥90	~0.7–1.0 mg/dL	Normal/high; kidney damage markers present
G2	60–89	~1.0–1.3 mg/dL	Mildly decreased
G3a	45–59	~1.3–1.7 mg/dL	Mildly-moderately decreased
G3b	30–44	~1.7–2.5 mg/dL	Moderately-severely decreased
G4	15–29	~2.5–5.0 mg/dL	Severely decreased
G5	<15	>5.0 mg/dL	Kidney failure/ESRD

Albuminuria	ACR (mg/g)	PCR (mg/g)	Risk
A1	<30	<150	Normal–mildly increased
A2	30–300	150–500	Moderately increased
A3	>300	>500	Severely increased

🎯 SECTION 2 — BLOOD PRESSURE TARGETS IN CKD

Clinical Context	BP Target
CKD without DM, ACR <30	<140/90 mmHg
CKD with albuminuria (ACR ≥30)	<130/80 mmHg
CKD with Diabetes	<130/80 mmHg
High CV risk CKD (SPRINT criteria)	<120 mmHg systolic if tolerated
CKD on Dialysis	<140/90 pre-dialysis
Post-Transplant CKD	<130/80 mmHg
ADPKD	<110/75 mmHg (HALT-PKD trial target)

💊 SECTION 3 — STEPWISE ANTIHYPERTENSIVE MANAGEMENT

🔷 MASTER FLOWCHART — Hypertension in CKD

╔══════════════════════════════════════════════════════════════════════╗
║           CKD PATIENT WITH ELEVATED BLOOD PRESSURE                  ║
╚══════════════════════════════╦═══════════════════════════════════════╝
                               ║
                               ▼
          ┌────────────────────────────────────────────┐
          │         BASELINE ASSESSMENT                │
          │  Labs: eGFR, Creatinine, K⁺, HCO₃⁻,      │
          │  CBC, LFT, Phosphate, Ca²⁺, PTH, HbA1c,  │
          │  Lipids, Urine ACR/PCR, Urine microscopy  │
          │  Imaging: Renal Doppler Ultrasound         │
          │  ECG, Echo if cardiac symptoms             │
          └────────────────────┬───────────────────────┘
                               ▼
          ┌────────────────────────────────────────────┐
          │     LIFESTYLE MODIFICATION (ALL STAGES)    │
          │  • Sodium intake <2 g/day (<90 mEq/day)   │
          │  • Low-protein diet: 0.8 g/kg/day          │
          │  • DASH/plant-based diet                   │
          │  • Weight loss if BMI >25                  │
          │  • Aerobic exercise 30 min, 5×/week        │
          │  • Smoking cessation (absolute)            │
          │  • Alcohol <2 units/day (men), <1 (women)  │
          │  • Glucose control: HbA1c <7%             │
          └────────────────────┬───────────────────────┘
                               ▼
                 ┌─────────────────────────┐
                 │   ALBUMINURIA PRESENT?  │
                 │     (ACR ≥30 mg/g)      │
                 └──────────┬──────────────┘
                           YES              NO
                            ▼               ▼
               ┌─────────────────┐  ┌──────────────────────┐
               │    STEP 1       │  │      STEP 1          │
               │ ACEi OR ARB     │  │ Amlodipine 5 mg/day  │
               │ (Ramipril 5mg   │  │ OR Chlorthalidone    │
               │  or Losartan    │  │    12.5 mg/day       │
               │  50 mg/day)     │  └──────────┬───────────┘
               └────────┬────────┘             │
                        └────────────┬──────────┘
                                     ▼
                      BP above target at 4–8 weeks?
                                     ▼ YES
              ┌──────────────────────────────────────────┐
              │                STEP 2                    │
              │  ACEi/ARB + CCB (Amlodipine 5–10 mg)   │
              │  (preferred combination in CKD)          │
              └──────────────────────┬───────────────────┘
                                     ▼
                      BP above target at 4–8 weeks?
                                     ▼ YES
              ┌──────────────────────────────────────────┐
              │                STEP 3                    │
              │  Add DIURETIC:                           │
              │  eGFR ≥30: Chlorthalidone 12.5–25 mg    │
              │  eGFR <30: Furosemide 40–80 mg BD        │
              │  Add SGLT2i (Dapagliflozin 10 mg) if    │
              │  eGFR ≥20 (renal + BP benefit)           │
              └──────────────────────┬───────────────────┘
                                     ▼
                      BP above target at 4–8 weeks?
                                     ▼ YES
              ┌──────────────────────────────────────────┐
              │    STEP 4: RESISTANT HYPERTENSION        │
              │                                          │
              │  First exclude:                          │
              │  • Poor adherence                        │
              │  • White-coat HTN (ABPM)                 │
              │  • Renal artery stenosis (Doppler)       │
              │  • Primary aldosteronism (ARR)           │
              │  • Obstructive sleep apnea               │
              │  • Thyroid disease, pheochromocytoma     │
              │                                          │
              │  ADD:                                    │
              │  Spironolactone 12.5–25 mg/day          │
              │    (if K⁺ <4.5, eGFR >30)               │
              │  OR Finerenone 10–20 mg/day             │
              │    (if DM + CKD, K⁺ ≤4.8, eGFR ≥25)    │
              │  OR β-blocker (Carvedilol 6.25 mg BD)   │
              │    (if HF/tachycardia/post-MI)           │
              │  OR Hydralazine 25 mg TID                │
              │  OR Minoxidil 5 mg/day (last resort)     │
              └──────────────────────────────────────────┘
                                     ▼
                    Nephrology referral if eGFR <30
                    or BP not controlled on 4 agents

💊 SECTION 4 — DRUG DOSING BY eGFR (Complete Tables)

🔴 ACE INHIBITORS

Drug	Normal Dose	eGFR 60–89	eGFR 30–59	eGFR 15–29	eGFR <15 / Dialysis
Ramipril	2.5–10 mg/day	Full dose	2.5–5 mg/day	1.25–2.5 mg/day	1.25 mg/day, caution
Lisinopril	10–40 mg/day	Full dose	5–20 mg/day	2.5–5 mg/day	2.5 mg/day
Enalapril	5–40 mg/day	Full dose	5–10 mg/day	2.5–5 mg/day	2.5 mg/day
Perindopril	4–8 mg/day	Full dose	2–4 mg/day	2 mg alt. days	Not recommended
Captopril	25–150 mg TID	Full dose	12.5–75 mg	6.25–25 mg	6.25 mg TID
Trandolapril	1–4 mg/day	Full dose	0.5–2 mg/day	0.5 mg/day	Avoid

Monitor: K⁺ and creatinine at 2 and 4 weeks after initiation. Creatinine rise <30% → acceptable, continue. Rise >50% → stop, investigate RAS.

🔴 ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)

Drug	Normal Dose	eGFR 30–59	eGFR 15–29	eGFR <15 / Dialysis
Losartan	50–100 mg/day	50–100 mg	25–50 mg	25 mg, monitor
Telmisartan	40–80 mg/day	40–80 mg	20–40 mg	20 mg (hepatic clearance — safer)
Valsartan	80–320 mg/day	80–160 mg	40–80 mg	40 mg
Candesartan	8–32 mg/day	8–16 mg	4–8 mg	Caution
Olmesartan	20–40 mg/day	20 mg	10–20 mg	10 mg
Irbesartan	150–300 mg/day	150–300 mg	75–150 mg	75 mg
Azilsartan	40–80 mg/day	40–80 mg	40 mg	Caution

⚠️ ACEi + ARB dual blockade is CONTRAINDICATED — ONTARGET trial: increased AKI, hyperkalemia, mortality without additional renal benefit.

🟡 CALCIUM CHANNEL BLOCKERS

Drug	Type	Normal Dose	CKD G3–G4	CKD G5/Dialysis
Amlodipine	DHP	5–10 mg/day	No adjustment	No adjustment
Nifedipine LA	DHP	30–90 mg/day	30–60 mg	30 mg
Felodipine	DHP	5–10 mg/day	5 mg	5 mg
Lercanidipine	DHP	10–20 mg/day	10 mg	10 mg
Diltiazem	Non-DHP	120–360 mg/day	120–180 mg	Reduce; caution
Verapamil	Non-DHP	120–360 mg/day	120–180 mg	Reduce dose

DHP-CCBs preferred. Non-DHPs (diltiazem, verapamil) reduce intraglomerular pressure and may reduce proteinuria, but use with ACEi/ARB can cause bradycardia.

🟡 DIURETICS

Drug	Class	Normal Dose	eGFR 45–60	eGFR 30–44	eGFR 15–29	eGFR <15
Chlorthalidone	Thiazide-like	12.5–25 mg/day	Full dose	12.5 mg/day	Reduced efficacy	Avoid
Hydrochlorothiazide	Thiazide	12.5–25 mg/day	12.5–25 mg	Less effective	Ineffective	Avoid
Indapamide	Thiazide-like	1.5–2.5 mg/day	Full dose	Full dose	Caution	Avoid
Furosemide	Loop	20–80 mg BD	40–80 mg BD	80–120 mg BD	80–160 mg BD	80–240 mg BD
Torsemide	Loop	5–20 mg/day	10–40 mg	20–40 mg	40–100 mg	100 mg
Bumetanide	Loop	0.5–2 mg BD	1–2 mg BD	2–3 mg BD	3–4 mg BD	Caution
Metolazone	Thiazide-like	2.5–5 mg/day	Full dose	2.5 mg	2.5 mg + loop	Synergy with loop

🔑 Key switch point: Transition from thiazide → loop diuretic at eGFR <30. Metolazone 2.5–5 mg added to loop diuretic creates powerful synergistic diuresis in resistant fluid overload.

🟠 MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRAs)

Drug	Type	Dose	eGFR Cutoff	K⁺ Prerequisite	Monitoring
Spironolactone	Non-selective	12.5–50 mg/day	≥30 mL/min	K⁺ <4.5 mEq/L	Weekly K⁺ ×4, then monthly
Eplerenone	Selective	25–50 mg/day	≥30 mL/min	K⁺ <4.5 mEq/L	Same
Finerenone	Non-steroidal	10 mg/day if eGFR 25–60	≥25 mL/min	K⁺ ≤4.8 mEq/L	K⁺ at 4 weeks
Finerenone	Non-steroidal	20 mg/day if eGFR ≥60	≥25 mL/min	K⁺ ≤4.8 mEq/L	K⁺ at 4 weeks

Finerenone (FIDELIO-DKD + FIGARO-DKD trials): Reduced kidney failure risk by 18% and CV death/MI/stroke by 13% in DM+CKD. Lower hyperkalemia risk than spironolactone due to non-steroidal structure.

🟠 BETA-BLOCKERS (Selective Use)

Drug	Indication	Dose	eGFR Adjustment
Carvedilol	HFrEF + CKD (preferred)	3.125–25 mg BD	No renal adjustment
Metoprolol succinate	HFrEF, post-MI, AF	25–200 mg/day	No renal adjustment
Bisoprolol	HF, rate control	2.5–10 mg/day	Reduce 50% if eGFR <20
Nebivolol	HTN + HF	2.5–10 mg/day	Start 2.5 mg; caution <30
Atenolol	HTN (less preferred)	25–100 mg/day	25 mg if eGFR <30; avoid dialysis or supplement post-HD
Labetalol	Hypertensive urgency	100–400 mg BD	No adjustment; IV in crisis

⚠️ Atenolol is renally cleared — accumulates in CKD. Prefer carvedilol or metoprolol.

🟤 DIRECT VASODILATORS & CENTRAL AGENTS

Drug	Class	Dose	CKD Notes
Hydralazine	Direct vasodilator	25–75 mg TID	No renal adjustment; use with β-blocker/diuretic to prevent reflex tachycardia
Minoxidil	Direct vasodilator	5–40 mg/day	Reserved resistant HTN; causes fluid retention — must combine with loop diuretic
Clonidine	Central α2-agonist	0.1–0.4 mg BD	Reduce by 50% if eGFR <10; risk of rebound HTN on withdrawal
Methyldopa	Central agonist	250–750 mg BD	Use with caution; reduce dose in CKD
Doxazosin	α1-blocker	1–8 mg/day	No adjustment; useful if BPH + HTN
Prazosin	α1-blocker	1–5 mg BD	Reduce starting dose in CKD

🧬 SECTION 5 — DRUGS TO SLOW CKD PROGRESSION

🔷 FLOWCHART — Renoprotective Strategy

╔══════════════════════════════════════════════════════════╗
║        CKD DIAGNOSED — SLOW PROGRESSION STRATEGY        ║
╚══════════════════════════╦═══════════════════════════════╝
                           ║
          ┌────────────────▼──────────────────┐
          │     Step 1: RAAS BLOCKADE         │
          │  ACEi OR ARB (not both)           │
          │  • Proteinuria ≥30 mg/g: MANDATORY│
          │  • Titrate to max tolerated dose  │
          │  • Monitor K⁺, Cr at 2–4 wks     │
          └─────────────────┬─────────────────┘
                            ▼
          ┌─────────────────────────────────────┐
          │   Step 2: SGLT2 INHIBITOR           │
          │  Dapagliflozin 10 mg/day            │
          │    (eGFR ≥25, DAPA-CKD trial)       │
          │  OR Empagliflozin 10 mg/day         │
          │    (eGFR ≥20, EMPA-KIDNEY trial)    │
          │  OR Canagliflozin 100 mg/day        │
          │    (eGFR ≥30, CREDENCE trial)       │
          │  Works in BOTH diabetic & non-      │
          │  diabetic CKD (DAPA-CKD, EMPA-KID) │
          └─────────────────┬───────────────────┘
                            ▼
          ┌─────────────────────────────────────┐
          │   Step 3: FINERENONE                │
          │  (if DM + CKD + albuminuria)        │
          │  10 mg/day if eGFR 25–60            │
          │  20 mg/day if eGFR ≥60              │
          │  Prerequisite: K⁺ ≤4.8 mEq/L       │
          │  Check K⁺ at 4 weeks               │
          └─────────────────┬───────────────────┘
                            ▼
          ┌─────────────────────────────────────┐
          │   Step 4: METABOLIC OPTIMIZATION   │
          │  • BP <130/80 mmHg                  │
          │  • HbA1c <7% (DM patients)          │
          │  • LDL <70 mg/dL (statin therapy)  │
          │  • Uric acid management             │
          │  • Treat metabolic acidosis         │
          │  • Treat anemia (ESA + iron)        │
          │  • Dietary protein 0.8 g/kg/day    │
          └─────────────────────────────────────┘

📋 DRUGS TO SLOW CKD PROGRESSION — Evidence Summary

Drug/Class	Mechanism	Indication	Key Trial	NNT/Benefit
ACEi / ARB	RAAS blockade, ↓ intraglomerular pressure	CKD + HTN + proteinuria	REIN, RENAAL, IDNT	32% ↓ ESRD risk
Dapagliflozin 10mg	SGLT2i, ↓ intraglomerular hyperfiltration, anti-inflammatory	CKD eGFR ≥25 (DM or non-DM)	DAPA-CKD	39% ↓ kidney failure/death
Empagliflozin 10mg	SGLT2i	CKD eGFR ≥20	EMPA-KIDNEY	28% ↓ progression/CV death
Canagliflozin 100mg	SGLT2i	DM + CKD, eGFR ≥30	CREDENCE	30% ↓ ESRD
Finerenone 10–20mg	Non-steroidal MRA	DM + CKD + albuminuria	FIDELIO + FIGARO	18% ↓ kidney failure; 13% ↓ CV events
Statin (Atorvastatin 20–40mg)	↓ LDL, anti-inflammatory, antiproteinuric	CKD G1–G4 all patients	SHARP, 4D	↓ CV events; modest GFR protection
Bicarbonate therapy	Corrects metabolic acidosis, ↓ ammoniagenesis	HCO₃⁻ <22 mEq/L	BICARB, BASE	Slows GFR decline by ~1 mL/min/yr
Low-protein diet (0.8 g/kg/day)	↓ hyperfiltration, ↓ uremic solute load	CKD G3b–G5 pre-dialysis	MDRD study	~0.5 mL/min/yr slower decline
Urate-lowering (Allopurinol)	↓ uric acid, anti-inflammatory	Hyperuricemia + CKD	PERL, CKD-FIX	Modest; reduces CRP/inflammation
GLP-1 RA (Semaglutide)	Weight + glucose + BP + anti-inflammatory	DM + CKD + obesity	FLOW (semaglutide)	24% ↓ kidney failure/death in DM
Bardoxolone	Nrf2 activator	CKD + DM	CARDINAL	↑ eGFR but HF signal; investigational

🔬 SECTION 6 — LAB-GUIDED DRUG DECISION FLOWCHART

════════════════════════════════════════════════════════════
          LAB VALUE → DRUG DECISION ALGORITHM
════════════════════════════════════════════════════════════

1. SERUM POTASSIUM (K⁺)
─────────────────────────────────────────────────────────
 K⁺ <4.0 mEq/L
   → Full dose ACEi/ARB; can add MRA (spironolactone)
   → If on diuretics: supplement K⁺ if <3.5 mEq/L

 K⁺ 4.0–4.5 mEq/L
   → Start ACEi/ARB at low dose
   → No MRA (spironolactone/eplerenone)
   → Finerenone acceptable if ≤4.8
   → Low-K⁺ diet, correct acidosis

 K⁺ 4.6–5.0 mEq/L
   → Reduce ACEi/ARB dose
   → Start Patiromer 8.4 g/day or SZC (Sodium
     Zirconium Cyclosilicate) 10 g TID ×3 days
     then 5 g/day maintenance → enables RAAS
   → Hold MRA

 K⁺ 5.1–5.5 mEq/L
   → Temporarily HOLD ACEi/ARB
   → Treat hyperkalemia (Patiromer/SZC/kayexalate)
   → Once K⁺ <5.0: restart at 50% dose
   → Loop diuretic to enhance K⁺ excretion

 K⁺ >5.5 mEq/L
   → STOP ACEi/ARB
   → Urgent hyperkalemia management:
     - Calcium gluconate (cardiac protection)
     - Insulin/dextrose
     - Sodium bicarbonate
     - Furosemide (if euvolemic/hypervolemic)
     - Kayexalate/Patiromer
     - Dialysis if K⁺ >6.5 or ECG changes

════════════════════════════════════════════════════════════

2. eGFR / CREATININE TRAJECTORY
─────────────────────────────────────────────────────────
 Creatinine rise <30% after ACEi/ARB
   → Acceptable hemodynamic effect — CONTINUE

 Creatinine rise 30–50%
   → Check: dehydration? NSAIDs? Contrast?
   → Renal Doppler to exclude bilateral RAS
   → Hold temporarily, re-challenge at lower dose

 Creatinine rise >50% or new AKI
   → STOP ACEi/ARB
   → Bilateral RAS must be excluded
   → Nephrology referral

 Rapid eGFR decline (>5 mL/min/year)
   → Refer nephrology
   → Renal biopsy consideration
   → Optimize all modifiable risk factors
   → Start SGLT2i if not already on

════════════════════════════════════════════════════════════

3. URINE ACR (Albumin:Creatinine Ratio)
─────────────────────────────────────────────────────────
 ACR <30 mg/g (A1)
   → CCB or thiazide as first-line acceptable
   → No mandatory RAAS (unless DM or HTN present)

 ACR 30–300 mg/g (A2)
   → ACEi OR ARB: MANDATORY first-line
   → Add SGLT2i (eGFR ≥20)
   → BP target <130/80 mmHg
   → Recheck ACR in 3 months

 ACR >300 mg/g (A3)
   → Maximize ACEi/ARB to full dose
   → Add SGLT2i + Finerenone (if DM)
   → Consider nephrology/renal biopsy
   → Dietary protein 0.8 g/kg/day
   → BP target <130/80 (aim <125/75 if tolerated)

════════════════════════════════════════════════════════════

4. HEMOGLOBIN / ANEMIA OF CKD
─────────────────────────────────────────────────────────
 Hb 10–12 g/dL (symptomatic)
   → Check: Ferritin, TSAT, B12, folate, retic count
   → If Ferritin <200 ng/mL or TSAT <20%:
     IV Iron (Ferric carboxymaltose 500–1000 mg IV)
   → If iron-replete: Start ESA therapy

 Hb <10 g/dL
   → IV iron FIRST (if iron-deficient)
   → ESA therapy:
     Erythropoietin alfa: 50–100 IU/kg 3×/week SC
     Darbepoetin alfa: 0.45 mcg/kg every 2 weeks SC
     Methoxy-PEG-EPO: 0.6 mcg/kg monthly
   → Target Hb: 10–11.5 g/dL (NOT >13 — CHOIR/CREATE)
   → ⚠️ ESA therapy raises BP — monitor and adjust
     antihypertensives after each dose change

 HIF-PHI (new class):
   Roxadustat / Daprodustat / Vadadustat
   → Oral agents; stimulate endogenous EPO
   → Used in dialysis patients; some non-dialysis

════════════════════════════════════════════════════════════

5. BICARBONATE / METABOLIC ACIDOSIS
─────────────────────────────────────────────────────────
 HCO₃⁻ 18–22 mEq/L
   → Sodium Bicarbonate 650 mg (8 mEq) BD–TID
   → Target HCO₃⁻: 22–26 mEq/L
   → Slows CKD progression; lowers K⁺

 HCO₃⁻ <18 mEq/L (severe)
   → Sodium Bicarbonate 1–3 g TID or
   → Sodium Citrate solution
   → Monitor Na⁺ (sodium load may worsen HTN/edema)

════════════════════════════════════════════════════════════

6. PHOSPHATE / CKD-MBD
─────────────────────────────────────────────────────────
 Phosphate >4.5 mg/dL (CKD G3b+)
   → Dietary phosphate restriction (<800 mg/day)
   → Phosphate binders WITH MEALS:
     Calcium carbonate: 500–1500 mg TID with meals
     Sevelamer carbonate: 800–1600 mg TID
     Lanthanum carbonate: 500–1000 mg TID
     Sucroferric oxyhydroxide: 500 mg TID
   → Avoid calcium-based binders if Ca²⁺ >9.5 mg/dL
     or vascular calcification present

 PTH elevated (secondary HPT)
   → CKD G3: Optimize Ca²⁺, PO₄, Vit D
   → CKD G4–G5: Active Vitamin D (Calcitriol 0.25–0.5 mcg/day)
   → CKD G5 dialysis: Cinacalcet 30–180 mg/day
   → Paricalcitol 1–2 mcg/day (IV, dialysis)
   → Parathyroidectomy if PTH >1000 pg/mL + refractory

════════════════════════════════════════════════════════════

7. LIPID MANAGEMENT
─────────────────────────────────────────────────────────
 CKD G1–G4: Statin therapy for ALL patients
   → Atorvastatin 20–40 mg/day (preferred, hepatic)
   → Rosuvastatin 10–20 mg/day (renally cleared; reduce to
     5–10 mg if eGFR <30)
   → Simvastatin/Ezetimibe 20/10 mg (SHARP trial — ↓ major
     atherosclerotic events in CKD)

 CKD G5 dialysis: No new statin initiation (4D/AURORA)
   → Continue statin if already on when starting dialysis

════════════════════════════════════════════════════════════

8. BLOOD GLUCOSE / DIABETES MANAGEMENT
─────────────────────────────────────────────────────────
 eGFR ≥45:
   → Metformin 500–2000 mg/day (full dose)
   → All SGLT2i can be used (check individual thresholds)

 eGFR 30–44:
   → Metformin REDUCE to max 1000 mg/day
   → Dapagliflozin/Empagliflozin (kidney protection —
     not glycemic — benefit persists to eGFR ≥20)

 eGFR <30:
   → STOP Metformin (lactic acidosis risk)
   → GLP-1 RA (Semaglutide, Liraglutide) — no dose
     adjustment needed (peptide-based clearance)
   → Insulin (titrate carefully — reduced renal clearance
     increases hypoglycemia risk)
   → Repaglinide 0.5–4 mg with meals (safest SU-type)
   → Avoid sulfonylureas (hypoglycemia risk)

🔊 SECTION 7 — RENAL ULTRASOUND IN CKD FOLLOW-UP

Parameters to Assess

Parameter	Normal	CKD Finding	Significance
Kidney length	9–12 cm	<9 cm (bilateral)	Advanced CKD; irreversibility
Cortical thickness	>7 mm	<7 mm	↓ nephron mass
Echogenicity	Iso-echoic to liver	Hyperechoic (brighter)	Fibrosis/scarring
Corticomedullary differentiation	Clear	Lost	Advanced parenchymal damage
Hydronephrosis	Absent	Unilateral or bilateral	Obstruction — urgent cause reversal
Cysts	0–1 simple	Multiple bilateral	ADPKD if >PKD1/2 criteria
Resistive Index (RI)	0.58–0.70	>0.70	Poor prognosis; high renovascular resistance
Renal artery PSV	<180 cm/s	>200 cm/s	Renal artery stenosis
Post-void residual	<50 mL	>150 mL	Bladder outflow obstruction contributing to CKD
Kidney asymmetry	<1.5 cm difference	>1.5 cm	Renovascular disease, RAS, reflux nephropathy
Echogenic foci	Absent	Present	Nephrocalcinosis, stones

🔷 ULTRASOUND FOLLOW-UP SCHEDULE

╔══════════════════════════════════════════════════════════╗
║              RENAL ULTRASOUND SCHEDULE                   ║
╠═══════════════╦══════════════╦══════════════════════════╣
║  CKD Stage    ║  Frequency   ║  Key Focus               ║
╠═══════════════╬══════════════╬══════════════════════════╣
║  G1–G2        ║  At diagnosis║  Structural anomalies,   ║
║  (eGFR ≥60)   ║  then q2–3yr ║  hydronephrosis, cysts   ║
╠═══════════════╬══════════════╬══════════════════════════╣
║  G3a–G3b      ║  Every       ║  Cortical thickness,     ║
║  (eGFR 30–59) ║  1–2 years   ║  RI, Doppler for RAS     ║
╠═══════════════╬══════════════╬══════════════════════════╣
║  G4           ║  Every       ║  Hydronephrosis, bladder,║
║  (eGFR 15–29) ║  6–12 months ║  AV fistula planning     ║
╠═══════════════╬══════════════╬══════════════════════════╣
║  G5/Pre-ESRD  ║  Every       ║  RRT planning, fistula   ║
║  (eGFR <15)   ║  3–6 months  ║  maturation, obstruction ║
╠═══════════════╬══════════════╬══════════════════════════╣
║  On Dialysis  ║  Annually    ║  Residual renal function,║
║               ║              ║  cysts, complications    ║
╚═══════════════╩══════════════╩══════════════════════════╝

SPECIAL CIRCUMSTANCES — Urgent Ultrasound:
 • BP refractory to ≥3 drugs → Doppler for RAS
 • Creatinine rise >30% on ACEi/ARB → Doppler for bilateral RAS
 • New oliguria or anuria → exclude obstruction
 • Suspected infection → for abscess/pyonephrosis
 • Flank pain + CKD → stones, obstruction
 • Asymmetric kidneys on exam → RAS evaluation

🩸 SECTION 8 — ADJUNCT DRUGS IN CKD (COMPLETE)

Drug Category	Drug(s)	Dose	Indication
Phosphate binders	Sevelamer carbonate	800–1600 mg TID with meals	Hyperphosphatemia G3b–G5
	Calcium carbonate	500–1500 mg TID	Hyperphosphatemia + hypocalcemia
	Lanthanum carbonate	500–1000 mg TID	Hyperphosphatemia; calcium-free
	Sucroferric oxyhydroxide	500 mg TID	Low pill burden option
Active Vit D	Calcitriol	0.25–0.5 mcg/day	Secondary HPT, G3b+
	Paricalcitol	1–2 mcg/day	Dialysis secondary HPT
	Alfacalcidol	0.25–1 mcg/day	CKD G4–G5
Calcimimetics	Cinacalcet	30–180 mg/day	Secondary HPT in dialysis
	Etelcalcetide	5–15 mg IV post-HD	Secondary HPT in HD patients
Alkalinizing agents	Sodium bicarbonate	650 mg–1 g TID	Metabolic acidosis (HCO₃⁻ <22)
	Sodium citrate	15–30 mL TID	Alternative to NaHCO₃
K⁺ binders	Patiromer	8.4 g/day (titrate to 25.2 g)	Hyperkalemia; enables RAAS use
	Sodium ZC (SZC)	10 g TID ×3 days, then 5 g/day	Acute + chronic hyperkalemia
	Sodium polystyrene sulfonate	15–60 g/day	Hyperkalemia (older agent, less preferred)
ESA / Anemia	Erythropoietin alfa	50–100 IU/kg 3×/week SC	Hb <10 g/dL, CKD anemia
	Darbepoetin alfa	0.45 mcg/kg q2weeks SC	Less frequent dosing
	Methoxy-PEG-EPO	0.6 mcg/kg monthly	Once-monthly option
	Roxadustat	70–200 mg TID	Oral HIF-PHI; dialysis anemia
IV Iron	Ferric carboxymaltose	500–1000 mg IV	Ferritin <200 or TSAT <20%
	Iron sucrose	100–200 mg IV	Weekly in dialysis
	Ferumoxytol	510 mg IV × 2 doses	Rapid repletion
Statins	Atorvastatin	20–40 mg/day	CV protection G1–G4
	Rosuvastatin	5–10 mg/day (if eGFR <30)	CV protection
	Simvastatin/Ezetimibe	20/10 mg/day	SHARP trial evidence
Antiplatelet	Aspirin 75–100 mg/day	Low dose	High CV risk CKD (not routine)
Urate-lowering	Allopurinol	100 mg/day (eGFR <30); 200–300 mg (G2–G3)	Hyperuricemia + CKD
	Febuxostat	40–80 mg/day	Safer in CKD G3–G4; caution CV risk
GLP-1 RA	Semaglutide SC	0.25–1 mg/week	DM + CKD; FLOW trial renal benefit
	Liraglutide	0.6–1.8 mg/day	DM + CKD; LEADER trial
	Dulaglutide	0.75–1.5 mg/week	DM + CKD
Vaccination	Hep B vaccine (×4 doses), Influenza annual, Pneumococcal	—	All CKD patients

🏥 SECTION 9 — INDICATIONS FOR DIALYSIS

🔷 FLOWCHART — When to Initiate Dialysis

╔══════════════════════════════════════════════════════════════╗
║              DIALYSIS INITIATION DECISION                   ║
╚═══════════════════════════╦══════════════════════════════════╝
                            ║
            ┌───────────────▼────────────────────┐
            │  ABSOLUTE (Emergency) INDICATIONS  │
            │  Start dialysis IMMEDIATELY:        │
            │                                    │
            │  A — Acidosis: pH <7.1 despite     │
            │       bicarbonate therapy           │
            │  E — Electrolytes: K⁺ >6.5 mEq/L  │
            │       or refractory hyperkalemia   │
            │  I — Intoxication: dialyzable       │
            │       drugs/toxins (methanol,       │
            │       ethylene glycol, salicylates, │
            │       lithium, theophylline)        │
            │  O — Overload (Volume): Pulmonary   │
            │       edema refractory to IV        │
            │       diuretics                     │
            │  U — Uremia:                        │
            │       • Pericarditis (fibrinous)    │
            │       • Uremic encephalopathy       │
            │       • Uremic bleeding/platelet    │
            │         dysfunction                 │
            │       • Nausea/vomiting impairing   │
            │         nutrition                   │
            └───────────────┬────────────────────┘
                            ▼
            ┌───────────────────────────────────────┐
            │  RELATIVE / ELECTIVE INDICATIONS      │
            │                                       │
            │  • eGFR <10 mL/min/1.73m² (G5)        │
            │    (initiate before symptoms develop) │
            │  • eGFR <15 with DM or poor residual  │
            │    function trajectory                 │
            │  • Progressive malnutrition/wasting   │
            │    despite dietary management         │
            │  • Refractory hypertension despite    │
            │    ≥4 antihypertensive agents          │
            │  • Refractory fluid overload          │
            │  • BUN >100 mg/dL persistently        │
            │    (with symptoms)                    │
            │  • Uncontrolled uremic symptoms       │
            │    (fatigue, neuropathy, pruritus)    │
            └───────────────┬───────────────────────┘
                            ▼
            ┌───────────────────────────────────────┐
            │   CHOOSE MODALITY:                    │
            │                                       │
            │  Hemodialysis (HD) ←— most common     │
            │    In-center: 3×/week                 │
            │    Home HD: 5–6×/week (short daily)  │
            │    Nocturnal HD: 6×/week overnight    │
            │                                       │
            │  Peritoneal Dialysis (PD)             │
            │    CAPD: 4 exchanges/day              │
            │    APD: nightly cycler                │
            │    Preferred: home, young, no         │
            │    abdominal adhesions                │
            │                                       │
            │  Kidney Transplantation               │
            │    Pre-emptive transplant             │
            │    (before dialysis) = BEST outcome   │
            └───────────────────────────────────────┘

📋 DIALYSIS PARAMETERS & ADEQUACY

Hemodialysis (HD)

Parameter	Standard	Target	Clinical Significance
Frequency	3×/week	3–6×/week	More frequent = better BP, less interdialytic weight gain
Session duration	3.5–4 hours	≥4 hours	Longer = better solute clearance, BP control
Dialysate flow (Qd)	500 mL/min	600–800 mL/min (high-flux)	Higher = better urea clearance
Blood flow (Qb)	300–400 mL/min	350–450 mL/min	Higher flow = better Kt/V
Kt/V (urea)	Target ≥1.2/session	1.2–1.4	Adequacy marker; <1.2 = underdialysis
URR (Urea Reduction Ratio)	>65%	>70%	Simple adequacy measure
Ultrafiltration rate	Variable	<13 mL/kg/hr	High UF rate → CV mortality
Dry weight	Patient-specific	Maintain/adjust	Assess by clinical exam + bioimpedance
Pre-dialysis K⁺	5.0–5.5 acceptable	<5.5	Lower K⁺ dialysate if hyperkalemia prone
Pre-dialysis BUN	<100 mg/dL target	—	Indicator of dialysis adequacy
Pre-dialysis BP	<140/90 mmHg	—	Cardiovascular risk reduction
Hemoglobin	10–12 g/dL	10–11.5 g/dL	Adjust ESA
Ferritin	200–500 ng/mL	—	IV iron supplementation
PTH (intact)	150–600 pg/mL in HD	2–9× upper normal	CKD-MBD management
Phosphate	<5.5 mg/dL	<4.5 mg/dL	Dietary + binders
Bicarbonate (post-HD)	22–26 mEq/L	—	Dialysate HCO₃ 30–35 mEq/L

Peritoneal Dialysis (PD)

Parameter	CAPD	APD/CCPD	Target
Exchanges/day	4 exchanges × 2L	Nightly cycler (4–6 cycles)	Continuous
Dwell time	4–6 hours	1.5–2 hours (night)	Per PD prescription
Weekly Kt/V urea	≥1.7/week	≥1.7/week	Adequacy standard
Creatinine clearance	≥50 L/week/1.73m²	≥50 L/week/1.73m²	Adequacy marker
Dialysate glucose	1.5%, 2.5%, 4.25%	Per fluid load	Adjust to ultrafiltration needs
UF volume/day	1–2L net positive	1–2L net positive	Volume management
Peritoneal equilibration test (PET)	Baseline + annually	—	High transporter = prefer APD
Exit site care	Daily cleaning	Daily	Prevent peritonitis
Peritonitis rate	Target <0.5 episodes/patient-year	—	Quality measure

📅 SECTION 10 — COMPLETE MONITORING SCHEDULE

╔════════════════════════════════════════════════════════════════════╗
║               CKD MONITORING TIMELINE                             ║
╠══════════════╦═══════════════════════════════════════════════════╣
║  PARAMETER   ║  G1–G2        G3a–G3b        G4          G5/RRT  ║
╠══════════════╬═══════════════════════════════════════════════════╣
║ BP           ║  Every visit  Every visit    Every visit  Daily  ║
║ eGFR/Cr      ║  Annually     q3–6 months    q3 months   Monthly ║
║ K⁺           ║  Annually     q3–6 months    q3 months   Monthly ║
║ Na/Cl/HCO₃  ║  Annually     q6 months      q3 months   Monthly ║
║ Urine ACR    ║  Annually     q6 months      q6 months   N/A    ║
║ Hemoglobin   ║  Annually     q6 months      q3 months   Monthly ║
║ Ferritin/    ║  Annually     Annually       q6 months   Monthly ║
║ TSAT         ║              ║              ║           ║        ║
║ Phosphate    ║  Annually     q6 months      q3 months   Monthly ║
║ Ca²⁺         ║  Annually     q6 months      q3 months   Monthly ║
║ PTH (intact) ║  Annually     Annually       q6 months   q3 mo   ║
║ Lipids       ║  Annually     Annually       Annually    Annually ║
║ HbA1c (DM)  ║  q3 months    q3 months      q3 months   q3 mo   ║
║ Uric acid    ║  Annually     q6 months      q6 months   q6 mo   ║
║ LFTs         ║  Annually     Annually       Annually    Annually ║
║ Renal US     ║  q2–3 years   q1–2 years     q6–12 mo   q3–6 mo  ║
╚══════════════╩═══════════════════════════════════════════════════╝

⚠️ SECTION 11 — CRITICAL DRUG INTERACTIONS IN CKD

Combination	Risk	Action
ACEi + ARB	AKI, severe hyperkalemia	Absolutely contraindicated
ACEi/ARB + NSAIDs	AKI, HTN loss of control, Na retention	Avoid all NSAIDs in CKD
ACEi/ARB + K-sparing diuretic	Severe hyperkalemia	Use only with K⁺ <4.5, frequent monitoring
SGLT2i + loop diuretic	Volume depletion, AKI	Ensure euvolemia before SGLT2i start
Metformin + eGFR <30	Lactic acidosis	Stop Metformin
Allopurinol + azathioprine	Bone marrow suppression	Reduce azathioprine by 75%
Digoxin in CKD	Toxicity (narrow TI, renally cleared)	Dose 0.0625 mg; check levels; avoid if eGFR <30
Gabapentin/Pregabalin in CKD	CNS toxicity, accumulation	Reduce dose: 100–300 mg/day if eGFR <30
Antibiotics (aminoglycosides)	Nephrotoxicity	Avoid or single daily dosing with TDM
Contrast media	Contrast nephropathy	Hydrate; use iso-osmolar; hold metformin
Lithium + CKD	Toxicity	Monitor levels; avoid if eGFR <30
Spironolactone + ACEi/ARB	Severe hyperkalemia	Only if K⁺ <4.5 and eGFR >30; weekly K⁺

🔁 SECTION 12 — NEPHROLOGY REFERRAL CRITERIA

Refer to Nephrology if ANY of the following:
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
 • eGFR <30 mL/min (CKD G4–G5) — mandatory
 • Rapid eGFR decline: >5 mL/min/year or >25% in <3 months
 • ACR >300 mg/g despite optimized therapy
 • Hematuria + proteinuria (glomerulonephritis?)
 • Hypertension uncontrolled on ≥3 agents
 • Suspected renal artery stenosis (creatinine rise on ACEi/ARB,
   asymmetric kidneys, resistant HTN)
 • CKD in young patient (<40 years)
 • Hereditary CKD (ADPKD, Alport syndrome)
 • AKI on CKD with unclear etiology
 • Pre-dialysis planning (start when eGFR 15–20)
 • Pre-transplant evaluation
 • Biopsy-proven or suspected GN requiring
   immunosuppression

References: Harrison's Principles of Internal Medicine 21st Ed. (pp. 8499, 8516); KDIGO 2021 CKD Blood Pressure Guidelines; KDIGO 2022 CKD Clinical Practice Update; ADA Standards of Diabetes Care 2022; DAPA-CKD Trial (NEJM 2020); EMPA-KIDNEY Trial (NEJM 2022); CREDENCE Trial (NEJM 2019); FIDELIO-DKD + FIGARO-DKD Trials (NEJM 2020/2021); FLOW Trial (semaglutide, NEJM 2024); SHARP Trial; Management of Cardiovascular Disease in Diabetes (ESC/EASD Guidelines 2023, p. 58).

This is a shared conversation. Sign in to Orris to start your own chat.